Literature DB >> 12053836

Thrombotic microangiopathies.

Daniel Halevy1, Jai Radhakrishnan, Glen Markowitz, Gerald Appel.   

Abstract

The thrombotic microangiopathies (TMA) are a group of diseases associated with microangiopathic hemolytic anemia, thrombocytopenia, and end-organ dysfunction. These seemingly disparate entities share in common a pathogenic mechanism involving endothelial injury and thrombus formation. Prognosis and treatment depend on the nature of the underlying disease.

Entities:  

Mesh:

Year:  2002        PMID: 12053836     DOI: 10.1016/s0749-0704(01)00004-5

Source DB:  PubMed          Journal:  Crit Care Clin        ISSN: 0749-0704            Impact factor:   3.598


  6 in total

1.  Deficiency in mouse hyaluronidase 2: a new mechanism of chronic thrombotic microangiopathy.

Authors:  Cécile Onclinx; Sophie Dogne; Laurence Jadin; Fabienne Andris; Christian Grandfils; François Jouret; François Mullier; Bruno Flamion
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

2.  The CXCR1/2 ligand NAP-2 promotes directed intravascular leukocyte migration through platelet thrombi.

Authors:  Mehran Ghasemzadeh; Zane S Kaplan; Imala Alwis; Simone M Schoenwaelder; Katrina J Ashworth; Erik Westein; Ehteramolsadat Hosseini; Hatem H Salem; Robyn Slattery; Shaun R McColl; Michael J Hickey; Zaverio M Ruggeri; Yuping Yuan; Shaun P Jackson
Journal:  Blood       Date:  2013-04-02       Impact factor: 22.113

3.  Plasma D-dimer concentration in patients with systemic sclerosis.

Authors:  Giuseppe Lippi; Alessandro Volpe; Paola Caramaschi; Gian Luca Salvagno; Martina Montagnana; Gian Cesare Guidi
Journal:  Thromb J       Date:  2006-01-18

4.  Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis.

Authors:  Julien Mahe; Aurélie Meurette; Anne Moreau; Caroline Vercel; Pascale Jolliet
Journal:  Drug Des Devel Ther       Date:  2013-08-07       Impact factor: 4.162

5.  Improvement in Gemcitabine-Induced Thrombotic Microangiopathy with Rituximab in a Patient with Ovarian Cancer: Mechanistic Considerations.

Authors:  Sangeetha Murugapandian; Babitha Bijin; Iyad Mansour; Sepehr Daheshpour; Biju G Pillai; Bijin Thajudeen; Abdulla K Salahudeen
Journal:  Case Rep Nephrol Dial       Date:  2015-06-26

6.  Drug-Immune Thrombocytopenia with Thrombosis versus Heparin-Induced Thrombocytopenia: A Critical Clinical Controversy.

Authors:  Hassan Al-Jafar; Anas Al-Yousef; Somaya Al-Shatti; Khalifa Al-Banwan
Journal:  Case Rep Nephrol Dial       Date:  2015-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.